Valuation: US Rare Earth Minerals Inc

Market Cap 2.94M 2.57M 2.37M 2.18M 4.12M 283M 4.21M 28.32M 11.12M 138M 11.03M 10.78M 477M P/E 2024
-5.27x
P/E 2025 -3.28x
Enterprise Value 3.68M 3.21M 2.97M 2.73M 5.15M 354M 5.27M 35.46M 13.93M 173M 13.81M 13.5M 597M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.38%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 73 2018-08-31
Director of Finance/CFO 65 2018-08-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 2018-11-01
Director/Board Member 73 2018-11-01
Chairman 73 2018-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-8.41%+3.57%+425.83% 23.29B
-0.09%-1.61%-18.68%-15.48% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-2.07%+24.79%+188.40% 14B
Average -2.77%-1.26%+44.14%+191.46% 26.72B
Weighted average by Cap. -2.92%-2.20%+43.58%+157.03%

Financials

2024 2025
Net sales - -
Net income -2.37M -2.07M -1.91M -1.76M -3.32M -228M -3.39M -22.83M -8.97M -112M -8.89M -8.69M -384M -2.12M -1.86M -1.71M -1.58M -2.98M -204M -3.04M -20.48M -8.04M -100M -7.97M -7.8M -345M
Net Debt 1.09M 952K 879K 809K 1.53M 105M 1.56M 10.5M 4.13M 51.33M 4.09M 4M 177M 741K 648K 598K 551K 1.04M 71.31M 1.06M 7.14M 2.81M 34.92M 2.78M 2.72M 120M
Logo US Rare Earth Minerals Inc
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
Employees
-